Edwards Lifesciences Q2 2026: $188M California Tax Charge Cuts GAAP EPS to $0.42 While Guidance Rises

Edwards Lifesciences reported net income from continuing operations of $241.4 million for the second quarter of 2026, down 28.1% from $335.9 million a year earlier, and diluted EPS of $0.42 against $0.57 — yet the underlying business did not weaken. (Total net income a year earlier was $331.5 million, or $333.2 million attributable to Edwards after noncontrolling interests, after a $4.4 million discontinued-operations loss.) Operating income rose 24.8% to $513.2 million on sales of $1,741.0 million — 13.6% reported growth, 12.5% in constant currency — and the operating margin reached 29.5%, the widest of the three second quarters this filing presents. The entire earnings decline traces to a single line: a $188.2 million non-cash valuation allowance against deferred tax assets, triggered by California budget legislation enacted on June 29 — one day before quarter-end. Edwards also raised full-year sales guidance alongside the results, and the shares rose roughly 6%. For a structural heart device maker whose growth thesis rests on procedure volume rather than the economic cycle, the distinction between a legislated tax write-down and an operating shortfall is what the market traded on.

Unless otherwise noted, all figures come from Edwards Lifesciences' Form 10-Q for the quarter ended June 30, 2026. Guidance, product-group sales and adjusted EPS come from the company's Q2 2026 earnings release (SEC Exhibit 99.1) and earnings call.

1. Balance Sheet: Options Convert Into Intangibles

1-1. Principal Asset Movements

The balance sheet ties exactly: total liabilities of $3,142.2 million plus equity of $10,724.9 million equals total assets of $13,867.1 million.

Three movements carry the meaning. Goodwill and intangibles rose a combined $437.0 million because two option positions converted into consolidated businesses. Edwards exercised its option over Autus Valve Technologies on February 6 for $128.9 million, adding $102.9 million of in-process R&D and $52.0 million of goodwill. On May 22 it amended agreements with a heart-failure device developer, gaining the power to direct that entity and consolidating it — adding $161.5 million of in-process R&D and $139.6 million of goodwill while holding only 26.7% of the shares. The two deals therefore added $191.6 million of goodwill against a net goodwill increase of $182.6 million on the balance sheet, and $264.4 million of in-process R&D. Acquisition options in other assets fell from $125.9 million to $11.7 million as those options converted into consolidated businesses and a third was terminated and written off in June.

Deferred tax assets fell $226.3 million, the balance-sheet footprint of the California valuation allowance. Receivables grew 16.8% against 13.6% sales growth, lifting days sales outstanding to roughly 40 days — a modest build, not a collection problem. Inventories were flat at $1,131.2 million, of which $221.9 million sits on consignment in hospitals. That consignment model is why inventory days look high for a manufacturer with 77% gross margins.

1-2. Debt Structure

Edwards carries almost no financial leverage. Long-term debt was $598.7 million, essentially unchanged from $598.3 million. Against $2,906.5 million of cash, $1,346.2 million of short-term investments and $244.1 million of long-term investments, the company holds a net cash position of roughly $3.9 billion. Operating lease liabilities total $105.7 million across current and long-term — immaterial to the capital structure.

Operating liabilities did the moving. Accrued and other liabilities fell 18.5% to $1,273.3 million, driven by employee compensation ($467.5M to $372.9M, the normal first-half bonus payout), the settlement of a $50.0 million litigation-settlement accrual that stood at year-end and is now nil, and the legal and insurance accrual line, which dropped from $164.2 million to $72.4 million. (That accrued-liabilities line item is broader than, and should not be confused with, the aggregate accrual for outstanding legal proceedings discussed in Section 4.) Working against that, uncertain tax positions rose from $502.7 million to $572.2 million.

1-3. Capital Structure

Retained earnings of $14,863.1 million dwarf paid-in capital of $3,637.6 million (common stock $661.7M plus additional paid-in capital $2,975.9M). This is a company financed almost entirely by its own accumulated profits. Treasury stock deepened from $7,091.7 million to $7,668.1 million as buybacks removed shares; shares outstanding fell from 580.7 million to 576.6 million despite issuance under stock plans. Noncontrolling interest — which Edwards already carried in smaller size, absorbing losses of $1.7 million in Q2 2025 and $3.3 million in H1 2025 — now stands at $106.9 million, reflecting the 73.3% of the consolidated heart-failure entity that Edwards does not own.

2. Income Statement: Operating Leverage Meets a Tax Wall

2-1. Second-Quarter Results

Q2 2024 figures as originally filed; restated for the final Critical Care discontinued-operations presentation they are sales of $1,369.4 million and operating income of $366.5 million, a 26.8% margin. Q2 2025 figures are unchanged from original filing. Quarters before 2024 are not comparable on this basis — they include the divested Critical Care group — so this filing supports margin comparisons back to 2024 only.

Sales grew 13.6% while operating income grew 24.8% — operating leverage of about 1.8 times, meaning each 1% of revenue growth converted into 1.8% of operating profit growth. Growth was concentrated in the transcatheter franchises: TAVR sales of $1.26 billion rose 11.3% as reported (10.5% constant currency), transcatheter mitral and tricuspid therapies (TMTT) reached $195.9 million, up 47.3% reported (44.8% constant currency), and Surgical added $284 million, up 6.5% reported (5.0% constant currency).

The margin source is mostly, though not entirely, operating expense. Gross margin held flat at 77.5%. R&D was nearly frozen at $278.9 million, up just 1.0%, falling from 18.0% to 16.0% of sales. SG&A rose 11.8% to $561.2 million, slower than revenue, easing from 32.8% to 32.2% of sales. Certain litigation expense fell from $15.5 million to $6.3 million in the quarter — though on a half-year basis it rose from $26.4 million to $43.4 million — and separation costs tied to the Critical Care divestiture ended entirely. Working the other way, other operating income shrank from $21.3 million to $11.0 million, a $10.3 million headwind.

Below the operating line the picture inverts. The bridge from operating income to pre-tax profit runs: $513.2 million of operating income, plus $30.0 million of net interest income (down from $37.4 million as rates eased), less a $40.0 million impairment on a terminated acquisition option, plus $16.6 million of other non-operating income that includes a $19.9 million mark-up on Edwards' previously held interest in the newly consolidated entity — $519.8 million of pre-tax income, up 29.9%. Then the tax provision jumped from $64.3 million to $278.4 million. The effective tax rate — tax as a share of pre-tax profit — went from 16.1% to 53.6%.

The cause is legislative, not operational. California enacted budget legislation on June 29 that permanently limits use of most business tax credits, including carried-forward R&D credits. Edwards concluded its California R&D credit carryforward is no longer realizable and wrote it off. Strip out that $188.2 million and quarterly net income would have been roughly $429.6 million, or about $0.74 per diluted share; Edwards itself sized the charge at roughly $0.32 per share against reported diluted EPS of $0.42. That arithmetic figure is not the company's non-GAAP number: Edwards reported adjusted EPS of $0.78, which also excludes intangible amortisation, the impairments discussed below and other items, and which beat the $0.74 analyst consensus. Reported EPS also benefited from a smaller share count: 577.6 million diluted shares versus 587.9 million.

A second tax item is recurring rather than one-off. Edwards expects the OECD's Pillar Two global minimum tax of 15% to add roughly $50.0 million of expense in 2026 before offsets, though the OECD's January 2026 Side-by-Side Safe Harbour package should reduce that as countries adopt it. Between Pillar Two and the California change, management guided the full-year effective tax rate to the high end of its original 16–19% range.

Crucially, the operating outlook improved rather than deteriorated. Edwards raised full-year 2026 constant-currency sales growth guidance to 10–11% from 9–11%, implying total sales of $6.6–$6.9 billion; lifted TAVR growth guidance to 8–9% ($4.75–$5.0 billion) and TMTT to $760–$780 million; and guided adjusted EPS to $2.95–$3.05. The shares rose roughly 6% on the print — the market read the tax charge exactly as this analysis frames it.

2-2. Cost Behaviour

The half-year data show the same shape. Sales rose 15.1% to $3,389.6 million while operating income rose 22.9% to $990.8 million, lifting the margin from 27.4% to 29.2%. The largely fixed cost base is R&D and stock-based compensation, which together ran $629.8 million in the first half against a $444.7 million increase in sales. Holding R&D growth to 2.1% in the first half — $542.2 million against $530.8 million — while sales compounded 15.1% is what produced the margin expansion. It is an effective lever, but one that cannot be pulled indefinitely at a company whose pipeline is its product.

Under US GAAP all internal R&D is expensed as incurred and cannot be capitalised, which makes Edwards' operating margin conservative relative to IFRS-reporting peers that capitalise development costs. The exception runs the other way: in-process R&D acquired through a business combination is recorded as an indefinite-lived intangible. Edwards added $264.4 million of such IPR&D this half, and it will be tested for impairment rather than amortised.

3. Cash Flow: Conversion Restored